Gertraud Stocker

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

Sylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag et al. · European Journal of Cancer · 2015 · 60 citations

Second-line Treatment, Arbeitsgemeinschaft Internistische Onkologie, Gastrointestinal Oncology +8

Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial

Ulrich Hacker, Dirk Hasenclever, Nicolas Linder et al. · Journal of Cachexia Sarcopenia and Muscle · 2019 · 59 citations · Full text

Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study

Florian Lordick, M. Mauer, Gertraud Stocker et al. · Annals of Oncology · 2024 · 29 citations · Full text

Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial

Matthias Ebert, Nadja M. Meindl‐Beinker, Tobias Gutting et al. · The Lancet Healthy Longevity · 2022 · 28 citations · Full text

Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study

Gertraud Stocker, Ulrich Hacker, Frédéric Fiteni et al. · European Journal of Cancer · 2018 · 24 citations

Petacc 3, Surgical Oncology, Gastrointestinal Oncology +10